| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2015: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Outline of Final Research Achievements |
We hypothesized that macrophages producing IFN-beta may be useful for anti-cancer therapy. However, it is impossible to amplify human peripheral blood monocytes and thus the quantity of macrophages generated by donated blood may be insufficient for clinical use. We established a method to induce proliferation of human iPS-cell derived myeloid cells (iPS-MC) by introduction of genes promoting cell proliferation to generate iPS-cell derived myeloid/macrophage cell line (iPS-ML).
When iPS-ML were injected into the mice with pre-established peritoneal tumors (xenograft model of peritoneally disseminated cancer), iPS-ML infiltrated into the tumor tissues. In xenograft models, iPS-ML introduced with an expression vector for IFN-beta (iPS-ML/IFN-beta) profoundly inhibited the growth of peritoneally disseminated human gastric and pancreatic cancer. In addition, therapy with iPS-ML/IFN-beta was effective in xenograft models of primary and metastatic liver cancer.
|
